Viewing 2 posts - 1 through 2 (of 2 total)
  • Author
  • #4644


      What can you tell us about the use of Shingrix in patients receiving immunotherapy? I know it probably hasn’t been studied yet in this setting, but do you suspect that it would be safer than Zostavax in this setting (theoretically)?


        HI Lisa- you ask an excellent question.

        – Shingrix is non-live, recombinant vaccine just recently approved for prevention of zoster.
        – Zostavax is a live, attenuated vaccine approved for prevention of zoster.

        Given the recommendation to avoid live vaccines while on immunotherapy, Shingrix would be the better of the two choices. Agreed- we do not have data regarding safety of use in the setting of immune therapy, specifically immune checkpoint inhibitors, but theoretically…..

        This may be an ideal option for patients at risk; and importantly, prevention of zoster prevents associated post-herpetic neuralgia—this is debilitating for some individuals.

        Thanks for posing this question Lisa.

      Viewing 2 posts - 1 through 2 (of 2 total)
      • You must be logged in to reply to this topic.

      Latest Activity